Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 10 of 10 publications.

Ahn JH, da Silva Pedrosa M, Lopez LR, Tibbs TN, Jeyachandran JN, Vignieri EE, Rothemich A, Cumming I, Irmscher AD, Haswell CJ, Zamboni WC, Yu YA, Ellermann M, Denson LA, Arthur JC. Intestinal E. coli-produced yersiniabactin promotes profibrotic macrophages in Crohn's disease. Cell Host Microbe. 2025 Jan 8;33(1):71-88.e9. doi: 10.1016/j.chom.2024.11.012

Barrows SM, Wright K, Copley-Merriman C, Kaye JA, Chioda M, Wiltshire R, Torgersen KM, Masters ET. Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer. Lung Cancer. 2019 Feb 8;2019:11-20. doi: 10.2147/LCTT.S179349

Horn L, Bauml J, Forde PM, Davis KL, Myall NJ, Sasane M, Dalal A, Culver K, Wozniak AJ, Baik CS, Mutebi A, Zhang P, Wakelee HA, Johnson BE. Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer. Lung Cancer. 2019 Feb;128(2019):74-90. doi: 10.1016/j.lungcan.2018.12.003

Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Chirila C, Hollis K, Sweeney C, Price M, Wolowacz S, Kaye JA, Kontoudis I. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: a retrospective observational study (LuCaBIS). Lung Cancer. 2018 Oct;124:298-309. doi: 10.1016/j.lungcan.2018.06.007

Chouaid C, Danson S, Andreas S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Price M, Chirila C, Hollis K, Sweeney C, Wolowacz S, Kaye JA, Kontoudis I. Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study. Lung Cancer. 2018 Oct;124:310-6. doi: 10.1016/j.lungcan.2018.07.042.

Du XL, Parikh RC, Lairson DR. Racial and geographic disparities in the patterns of care and costs at the end of life for patients with lung cancer in 2007–2010 after the 2006 introduction of bevacizumab. Lung Cancer. 2015 Dec;90(3):442-50.

Davis KL, Goyal RK, Able SL, Brown J, Li L, Kaye JA. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer. Lung Cancer. 2015 Feb;87(2):176-85. doi: 10.1016/j.lungcan.2014.11.002

Herring WL, Herrmann JW. The single-day surgery scheduling problem: sequential decision-making and threshold-based heuristics. OR spectrum: quantitative approaches in management. 2012 Apr 1;34(2):429-59.

Cella D, Eton DT, Fairclough DL, Heyes AE, Silberman C, Wolf MK. What is a clinically meaningful change (CMC) on the Functional Assessment of Cancer Therapy - Lung (FACT-L): analysis of ECOG 5592 data. Poster presented at the 7th Central European Lung Cancer Conference; June 2001. Prague, Czech Republic. [abstract] Lung Cancer. 2001 May; 32(Suppl 1):52.

Cella D, Eton DT, Fairclough DL, Heyes AE, Silberman C, Bonomi P, Wolf MK. What is a clinically meaningful change (CMC) on the Functional Assessment of Cancer Therapy (lung) (FACT-L): analysis of ECOG 5592 data. Lung Cancer. 2001;373-6.